Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Beurskens

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Immunology Today|April 1, 1997
Does complement component C4A protect from autoimmune disease?F J Beurskens, H van Dijk, D M Robins
Pediatric Research|May 19, 1998
Antibody responses and opsonic activity in sera of preterm neonates with coagulase-negative staphylococcal septicemia and the effect of the administration of fresh frozen plasmaT G Krediet, F J Beurskens, H van Dijk, et al.
European Journal of Immunology|May 23, 2000
Mouse complement components C4 and Slp act synergistically in a homologous hemolytic C4 assayF J Beurskens, M Tosi, T Shiroisho, et al.
Clinical and Experimental Immunology|June 11, 1999
Sex-limited protein: in vitro and in vivo functionsF J Beurskens, J D Kuenen, F Hofhuis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 11, 2018
Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells"Patrick J Engelberts, Esther C W Breij, T Valerius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Clinical and Experimental Immunology|December 20, 2019
Carbamylation reduces the capacity of IgG for hexamerization and complement activationR Lubbers, S C Oostindie, D J Dijkstra, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Immunology Today|April 1, 1997
Does complement component C4A protect from autoimmune disease?F J Beurskens, H van Dijk, D M Robins
Pediatric Research|May 19, 1998
Antibody responses and opsonic activity in sera of preterm neonates with coagulase-negative staphylococcal septicemia and the effect of the administration of fresh frozen plasmaT G Krediet, F J Beurskens, H van Dijk, et al.
European Journal of Immunology|May 23, 2000
Mouse complement components C4 and Slp act synergistically in a homologous hemolytic C4 assayF J Beurskens, M Tosi, T Shiroisho, et al.
Clinical and Experimental Immunology|June 11, 1999
Sex-limited protein: in vitro and in vivo functionsF J Beurskens, J D Kuenen, F Hofhuis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 11, 2018
Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells"Patrick J Engelberts, Esther C W Breij, T Valerius, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Clinical and Experimental Immunology|December 20, 2019
Carbamylation reduces the capacity of IgG for hexamerization and complement activationR Lubbers, S C Oostindie, D J Dijkstra, et al.
Pageof 1